SCOPUS 정보 검색 플랫폼

Journal of Rheumatology

Volumn 36, Issue 9, 2009, Pages 2110-2113

Observations from the OMERACT Drug Safety Summit, May 2008

(6) Simon, Lee S a Strand, C Vibeke b Boers, Maarten c Brooks, Peter M d Henry, David e Tugwell, Peter S f

a HARVARD MEDICAL SCHOOL (United States)

b STANFORD UNIVERSITY (United States)

c VU UNIVERSITY MEDICAL CENTER (Netherlands)

d UNIVERSITY OF QUEENSLAND (Australia)

e Institute for Clinical and Evaluative Sciences (Canada)

f UNIVERSITY OF OTTAWA (Canada)

Author keywords

Clinical trials; Drug safety; Pharmacoepidemiology; Risk assessment

Indexed keywords

CONFERENCE PAPER; DRUG SAFETY; HUMAN; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

ANTIRHEUMATIC AGENTS; DRUG DISCOVERY; DRUG TOXICITY; HUMANS; RHEUMATIC DISEASES; RISK ASSESSMENT;

EID: 70349230070 PISSN: 0315162X EISSN: None Source Type: Journal
DOI: 10.3899/jrheum.090590 Document Type: Conference Paper

Times cited : (6)

References (6)

1
- 70349230070
- Proceedings of the OMERACT 9 Drug Safety Summit:controversies and concerns about how to ascertain drug safety in the context of benefit
- Simon LS, Strand CV, Boers M, et al. Proceedings of the OMERACT 9 Drug Safety Summit:controversies and concerns about how to ascertain drug safety in the context of benefit. J Rheumatol 2009;36:2110-2113
- (2009) J Rheumatol , vol.36 , pp. 2110-2113
- Simon, L.S.¹ Strand, C.V.² Boers, M.³

2
- 70349262889
- March 5, Internet. Accessed May 14, 2009. Available from
- US Food and Drug Administration Advisory Committee. Briefing information regarding Arava®; March 5, 2003. [Internet. Accessed May 14, 2009.] Available from: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3930b2.htm
- (2003) Briefing Information Regarding Arava®

3
- 0031527873
- A look at the rule of three
- Javonovic BD, Levy PS. A look at the rule of three. Am Statistician 1997;51:137-139
- (1997) Am Statistician , vol.51 , pp. 137-139
- Javonovic, B.D.¹ Levy, P.S.²

4
- 0019519866
- Empiric delineation of the probability spectrum of adverse drug reactions
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245 (Pubitemid 11140804)
- (1981) Clinical Pharmacology and Therapeutics , vol.29 , Issue.2 , pp. 267-268
- Naranjo, C.A.¹ Busto, U.² Abel, J.G.³ Sellers, E.M.⁴

5
- 0031472193
- Causal or Casual? the role of causality assessment in pharmacovigilance
- Meyboom RH, Hekster YA, Egberts AC, Gribnau FW, Edwards IR. Causal or Casual? The role of causality assessment in pharmacovigilance. Drug Safety 1997;17:374-389
- (1997) Drug Safety , vol.17 , pp. 374-389
- Meyboom, R.H.¹ Hekster, Y.A.² Egberts, A.C.³ Gribnau, F.W.⁴ Edwards, I.R.⁵

6
- 3042651139
- Grading quality of evidence and strength of recommendations
- the GRADE Working Group
- Atkins D, Best D, Briss P, et al, and the GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490-1499
- (2004) BMJ , vol.328 , pp. 1490-1499
- Atkins, D.¹ Best, D.² Briss, P.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.